IPIC Message Board - Msg: 5514065

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IPIC

IPIC 0.0001000

0.0%

Aug 15 3:35 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: margaret foley who wrote (1256)	8/17/1998 9:18:00 AM
From: margaret foley	Read Replies (1) of 1359

Interneuron's Pagoclone Significantly Reduces Panic Attacks in Phase 2/3 Clinical Trial Drug Achieves Primary Endpoint, Advances in Clinical Development LEXINGTON, Mass.--(BW HealthWire)--August 17, 1998-- Interneuron Pharmaceuticals, Inc. (NASDAQ:IPIC - news) today announced results of a Phase 2/3 trial showing that treatment with pagoclone, a novel GABA receptor modulator, statistically significantly reduced the frequency of panic attacks among patients suffering from panic disorder. In addition, pagoclone was well-tolerated by these patients, with no evidence of sedation and no apparent withdrawal symptoms in this study, which included a tapering-off period. Based on the results of this trial, Interneuron has identified an optimal dose of pagoclone for Phase 3 clinical testing.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next